Inclusion Criteria:

- Patient must have participated on a deforolimus parent trial

- Patients must have derived a clinical benefit from the parent trial

- Patient is not on any other anti-cancer treatment(s) unless the therapy was allowed
on the parent protocol

- ECOG performance status less than or equal to 2 if the patient is scheduled to
receive treatment with deforolimus; no requirement if the patient is included for
follow-up purposes only

- Patients of childbearing potential must have a negative pregnancy test within 7 days
prior to screening and must use approved contraceptive from screening until 30 days
after the last dose of study drug

- Signed informed consent

Exclusion Criteria:

- Has not participated on a parent trial

- Women who are to receive study drug who are pregnant or lactating

- Any condition in the Investigator's judgment that renders the patient unable to fully
understand and provide informed consent and/or comply with the protocol